Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier

    iCMLf Forum 2016 Webstreams iCMLf Forum 2016 Podium

    Webstreams of the presentations from the iCMLf Forum for Physicians from Emerging Regions 2016 are now available to view. This year's Forum focused on 'Managing the high risk CML patient'. Presenters give the local emerging regions perspectives on each topic followed iCMLf experts and a discussion with the audience.

    Topics include:

    1. Meeting the new challenges in CML therapy 
      Professor Brian Druker (USA) 
    2. Frontline therapy challenges 
      Professor Tapan Saikia (India) and Professor Andreas Hochhaus (Germany)
    3. Comorbidities when managing CML
      Dr Anthony Oyekunle (Botswana) and Dr Delphine Réa (France)

    Click on the presentations below to view the webstreams and see the slides.
    (We are very grateful for the support of Brandcast media to produce these web streams) 



    iCMLf Forum 2016 Brian Druker

    Prof. Brian Druker
    Portland, USA

    Keynote: Meeting the new challenges in CML therapy 

    Topics and questions raised include; current state of CML, challenges for patients on long-term therapy, How can we move from control to cure?, Do we need to eradicate stem cells?, Can the immune system control CML?, challenges for clinical trials.






    iCMLf Forum 2016 Tapan Saikia

    Prof. Tapan Saikia
    Mumbai, India

    Frontline therapy challenges:
    High-risk chronic myeloid leukemia: An emerging country's perspective

    Topics include; high-risk CML cases, current treatment for high-risk CML-CP: Indian scenarios, availability of TKI's for CML in India, possibilities of using TKI's in high risk CML in India, challenges in managing high-risk patients. 





    iCMLf Forum 2016 Andreas Hochhaus

    Prof. Andreas Hochhaus
    Jena, Germany

    Frontline therapy challenges

    Topics include; challenge 1: initial therapy, challenge 2: additional therapy to avoid adverse events, challenge 3: prognostic score, challenge 4: unfavourable bone marrow data, challenge 5: choice of initial therapy, case studies on tests to start TKI and follow-up. 




    iCMLf Forum 2016 Pat Garcia Gonzalez

     Pat Garcia-Gonzalez

    Seattle, USA

    Q&A Session 1: Frontline therapy challenges  

    Moderated by Pat Garcia-Gonzalez, CEO The MAX Foundation                                       





    iCMLf Forum 2016 Anthony OyekunleDr Anthony Oyekunle
    Gaborone, Botswana

    Comorbities when managing CML with TKI's:
    An emerging country's perspective 

    Topics include; managing CML with TKI's, the case for comorbities, What is the impact of comorbidities on overall survival in CML? key outcomes from various studies, conclusion.






    iCMLf Forum 2016 Delphine Rea.pngDr Delphine Réa
    Paris, France

    Managing CML patients with comorbidities

    Topics include; prevalence of comorbidities among CML patients, impact of comorbidities on 1st line imatinib efficacy in CP-CML, impact of comorbidities on overall survival after 1st line imatinib treatment in CP-CML, results from the DASISION and ENESTnd trials, discussion on comorbidities may guide TKI choice in the first line seeting, conclusion. 






    iCMLf Forum 2016 Pat Garcia Gonzalez
    Pat Garcia-Gonzalez
    Seattle, USA

    Q&A Session 2: Comorbidities when managing CML 

     Moderated by Pat Garcia-Gonzalez, CEO The MAX Foundation